Advancing Precision Medicine in Psoriatic Arthritis: HIPPOCRATES Project Progress

The HIPPOCRATES project is making significant strides in improving outcomes for people living with psoriatic arthritis (PsA).

By addressing four key unmet needs—early diagnosis, risk assessment for progression from psoriasis to PsA, identifying rapid disease progression, and predicting treatment response—HIPPOCRATES aims to intentify biomarkers and develop clinical tools that will transform PsA care.

HIPPOCRATES brings together a multidisciplinary consortium of researchers, clinicians, industry partners, and patient representatives, working across eight interconnected work packages. A major achievement has been the establishment of a Europe-wide library of clinical biosamples and associated data. The signing of the HIPPOCRATES Data Sharing Agreement (DSA) in 2023 enabled the consolidation of clinical and molecular data into a central Secure Data Management Platform, now hosting data from 2,284 patients.

Key scientific advancements include launching the HIPPOCRATES Prospective Observational Study (HPOS) to predict psoriasis-to-PsA conversion, with over 3,000 participants recruited across multiple European countries. A pilot study investigating molecular markers for PsA progression has also been completed, with findings presented at a major rheumatology congress. Additionally, three cross-disciplinary working groups have made substantial progress in clinical data harmonization, biomarker discovery, and imaging analysis.

With 33 peer-reviewed publications and 39 presentations, HIPPOCRATES is already making a significant impact. Ultimately, the project aims to deliver diagnostic algorithms and precision medicine tools that will improve early diagnosis, treatment selection, and disease management—offering tangible benefits for patients, clinicians, and healthcare systems alike.

For more details, check out the whole summary.